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CLINICAL ARTICLE
Obstetrics

Impact of maternal vaccination timing and influenza virus
circulation on birth outcomes in rural Nepal
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Subarna K. Khatry4 | Laxman Shrestha5 | Jane Kuypers6 | Luke C. Mullany1 |
Helen Y. Chu7 | Steven C. LeClerq1,4 | James M. Tielsch8
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Abstract
Objective: To describe the effect of maternal vaccination on birth outcomes in rural

2

Seattle Children’s Hospital and Research
Foundation, University of Washington, Seattle,
WA, USA

Nepal, modified by timing of vaccination in pregnancy and influenza virus activity.

3

a randomized controlled trial. A total of 3693 pregnant women from Sarlahi District

Department of Pediatrics, Cincinnati
Children’s Hospital Medical Center, Cincinnati,
OH, USA
4
Nepal Nutrition Intervention Project –
Sarlahi, Kathmandu, Nepal

Methods: A secondary analysis was conducted using data from two annual cohorts of
were enrolled between April 25, 2011, and September 9, 2013. All participants were
aged 15–40 years and received a trivalent inactivated influenza vaccine or placebo.
The outcome measures included birth weight, pregnancy length, low birth weight

5

Department of Pediatrics and Child
Health, Institute of Medicine, Tribhuvan
University, Kathmandu, Nepal

(<2500 g), preterm birth, and small-for-gestational-age birth.

6

for 3623 births. Maternal vaccination increased mean birthweight by 42 g (95% confi-

Results: Data were available on birth weight for 2741 births and on pregnancy length

Molecular Virology Laboratory, School of
Medicine, University of Washington, Seattle,
WA, USA

dence interval [CI] 8–76). The magnitude of this increase varied by season but was
greatest among pregnancies with high influenza virus circulation during the third tri-
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mester. Birth weight increased by 111 g (95% CI −51 to 273) when 75%–100% of

8
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a pregnancy’s third trimester had high influenza virus circulation versus 38 g (95% CI
−6 to 81) when 0%–25% of a pregnancy’s third trimester had high influenza virus
circulation. However, these results were nonsignificant.
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weight; the magnitude appeared larger during periods of high influenza virus circulation.
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1 | INTRODUCTION

One study showed markedly increased innate and adaptive
immune responses to the influenza vaccine when comparing pregnant

In 2010, influenza infection accounted for 19 200 000 disability-
1

with non-pregnant women,4 suggesting that these responses might

adjusted life years worldwide. Pregnant women are at particularly

underpin increased rates of morbidity and mortality among pregnant

high risk of complications from influenza infection.2 WHO recom-

women. Furthermore, worse health outcomes resulting from influ-

mends vaccination for pregnant women.

3

enza infection has been reported during late stages of pregnancy than

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited.
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during early stages.5 Maternal influenza infection has also been linked
with fetal growth restriction, preterm delivery, and fetal loss.

6

a week between 17 and 34 weeks of pregnancy at which they would
undergo vaccination. Pregnancy length was calculated from the date

Neonates born growth restricted and/or preterm are likely to

of the last menstrual period; recall of the date was aided by 5-weekly

experience both immediate and long-term health consequences.

population pregnancy surveillance by the study staff. Women in both

Those born small-for-gestational-age (SGA)—a proxy for fetal growth

cohorts were randomly allocated to receive a trivalent inactivated

restriction—experience increased risk of neonatal and infant mortality,

influenza vaccine or saline placebo in blocks of eight, stratified by

stunted growth, and chronic disease in adulthood.7,8 Likewise, those

pregnancy length at vaccination (17–25 or 26–34 weeks). The partic-

born preterm have increased risk of neonatal and infant mortality, as

ipants were masked to their allocation. Two different formulations of

well as cognitive and motor impairments.8,9

the vaccine were used (second formulation used starting from October

Observational studies and randomized controlled trials (RCTs)

15, 2012). Details on the vaccines are available in Appendix S1.

exploring the effect of maternal influenza vaccination on rates of SGA

All enrolled women were visited weekly by study staff, both during

and preterm delivery have reported mixed findings.10–15 The Nepal

and after pregnancy (follow-up continued to 180 days after delivery),

Mothers’ Gift Trial was an RCT of maternal influenza vaccination with

to collect data on maternal and infant morbidities for each day in the

two annual cohorts of pregnant women residing in a rural area of this

previous week. These illness signs were all self-reported by the women

country.15,16 The primary outcomes were maternal influenza-like ill-

or other household members. Influenza-like illness was defined as a

ness, infant influenza infection, and low birth weight (LBW; defined

fever in the presence of either a cough or sore throat, based on daily

as <2500 g). Inconsistent results were found between the two annual

self-reported data that was collected on a weekly basis. Nasal swabs

cohorts; however, protective effects were reported in at least one of

were taken for influenza testing by polymerase chain reaction17

these cohorts for all outcomes assessed.

15

among all women presenting with fever plus one additional morbidity

The aim of the present analysis was to present further details of

sign (persistent cough, sore throat, nasal congestion, or myalgia) and

the effect of maternal influenza vaccination on birth weight and preg-

all infants with fever, cough, wheezing, difficulty in breathing, or otor-

nancy length among participants enrolled in the Nepal Mothers’ Gift

rhea on any of the previous 7 days. Details of the laboratory tests are

Trial. The effect of maternal vaccination on birth outcomes and its

available elsewhere.15

modification by pregnancy length at which vaccination was given and

The participants were instructed to notify study staff immediately

by influenza virus activity were assessed. These issues are particularly

after delivery, at which time a staff member visited the household to

important to address in locations with year-round influenza circulation

collect data on maternal, fetal, and neonatal status, as well as morbid-

to determine the ideal timing of maternal vaccination.

ities and conditions during labor and delivery.
The main outcome measures were birth weight and pregnancy

2 | MATERIALS AND METHODS

length at delivery, and dichotomous variables LBW, preterm delivery
(<37 weeks), and SGA. Only neonatal weights taken within 72 hours
of delivery were included; when weight was taken beyond 72 hours,

A secondary analysis was performed using the data from an RCT that

data on pregnancy length could still be contributed. A birth weight

examined the efficacy of influenza immunization on the incidence of

lower than the 10th percentile of the sex-specific and gestational-

respiratory illness and laboratory-confirmed influenza infection among

age-specific INTERGROWTH-21st birth weight standard18 was used

pregnant women and their neonates, with 6 months of postpartum fol-

to define SGA. Neonates at or above the 10th percentile were catego-

low-up.15,16 Ethical approval was obtained for the original study and sub-

rized as appropriate-for-gestational-age (AGA).

sequent analyses from the Institutional Review Boards of the Cincinnati

The data were analyzed using Stata version 13 (StataCorp, College

Children’s Medical Center (Cincinnati, OH, USA), Johns Hopkins

Station, TX, USA). The distribution of birth weight and pregnancy length

Bloomberg School of Public Health (Baltimore, MD, USA), the Institute

at delivery was summarized by vaccination group. The data were also

of Medicine at Tribhuvan University (Kathmandu, Nepal), and the Nepal

stratified by the formulation of the vaccine the mother received. The

Health Research Council (Kathmandu, Nepal). All participants provided

infants were categorized by creating mutually exclusive categories of

informed consent to the original study and use of data for analysis.

delivery weight and pregnancy length as follows: term-AGA-not LBW,

Full details of the original methods and the results for the primary

term-AGA-LBW, term-SGA-not-LBW, term-SGA-LBW, preterm-AGA-

outcomes have been described elsewhere.15,16 Briefly, married, preg-

not-LBW, preterm-AGA-LBW, and preterm-SGA (Fig. S1).8 Infants in

nant women aged 15–40 years living in Sarlahi District, Nepal, were

the preterm-SGA group were all LBW. The regression analyses con-

invited to participate. Women who had already received influenza

ducted are summarized in Table 1.

vaccination that season, planned to deliver outside the study area, or
had allergies to vaccine components (e.g. egg) were excluded. Eligible
women were enrolled in two separate but sequential annual cohorts.

3 | RESULTS

For the first cohort, women at 17–34 weeks of pregnancy were
enrolled between April 25, 2011, and April 24, 2012, and vaccinated

The flow diagrams for the two annual cohorts are shown in Figures S2

on enrollment. For the second cohort, women were enrolled between

and S3. A total of 3693 pregnant women were enrolled; 1846 received

April 25, 2012, and April 24, 2013; they were then randomly assigned

placebo and 1847 received the influenza vaccine. The 17 deliveries that

Adjusted linear regression

1) Linear regression;
2) Log-binomial regression;
3) Multinomial regression

Determine association
between maternal
influenza or influenza-like
illness and birth outcomea

Association between
influenza vaccination and
birth outcome

Vaccination status (influenza
vaccination or placebo)

1) Laboratory-confirmed influenza
at any point during pregnancy;
2) Influenza-like illness at any point
during pregnancy;
3) Total days of illness for
laboratory-confirmed influenza;
4) Total days of illness for
influenza-like illness

Independent variable(s) of interest

1) Birth weight, pregnancy length as
continuous outcomes
2) LBW, preterm, and SGA as
binary outcomes
3) LBW-preterm-SGA categories as
outcomes, using term-AGA-not
LBW as the reference

Birth weight

Dependent variable of interest

• Stratified by 4-mo groupings of calendar time the 
vaccination was provided, as there is seasonal variation in
the birth outcomes
• Stratified by maternal exposure to high, low, or no influenza
circulationc during the 3rd trimester (≥28 wk), given that the
speed of fetal weight gain is greatest in the 3rd trimester
• Stratified by whether the mother had 0 to <25%, 25 to
<50%, 50 to <75%, or 75 to ≤100% of their 3rd trimester
exposed to high circulation
• Examined the interaction between exposure to high
influenza circulation (percentage of 3rd trimester exposed to
high influenza circulation) and vaccination and subsequently
stratified the circulation analyses by when women were
vaccinated in pregnancy (<26, 26 to <30, or ≥30 wk)

—

Stratified analyses

Abbreviations: LBW, low birth weight; SGA, small for gestational age; AGA, appropriate for gestational age.
a
Analysis treated as observational study. Remaining analyses treated as randomized controlled trial.
b
Adjusted for parity, maternal height, infant sex, seasonality of time of birth, and mother’s age at first marriage.
c
Each calendar week of the study period was categorized as high, low, or no influenza circulation. High circulation was defined as ≥0.25% of all enrolled mothers or infants contributing morbidity data that week
testing positive for influenza, low circulation as >0% to <0.25%, and no circulation as 0%.

b

Regression model

Description of analyses.

Objective

TABLE 1
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occurred within 2 weeks of the mothers receiving the vaccine were

proportions in the high-risk categories (term-SGA-LBW, preterm-AGA-

excluded from the present analysis on the assumption that immunologic

LBW, and preterm-SGA). The results of the regression analyses reflected

protection after vaccination requires 2 weeks for full effect. The num-

these reductions, but were not statistically significant (Table 3).

ber of eligible live births was 1826 in the placebo group and 1820 in the

Figure 1 displays the bimonthly mean birth weight in the placebo

vaccinated group. Birth weight was measured within 72 hours of deliv-

and vaccinated groups versus weekly influenza virus circulation. Figure

ery among 1361 (74.5%) women in the placebo group and 1380 (75.8%)

S5 shows the same graph but with circulation levels stratified by the

in the vaccination group. Furthermore, 1813 (99.3%) women in the pla-

type of influenza virus. Generally, there were patterns of increased dif-

cebo group and 1810 (99.5%) in the vaccination group had a pregnancy

ferences in birth weight, comparing vaccination with placebo, at times

length within the predefined feasibility range (24 to <50 weeks).

of high circulation for each viral strain.

Among the 2741 women whose newborns were weighed within

With regard to secular trends, the mean birth weight increased by

72 hours of delivery, 31 (1.1%) had at least one laboratory-confirmed

5 g (95% CI 2–8) per month for the placebo group and 7 g (95% CI 4–10)

influenza episode during pregnancy whereas 2710 (98.9%) did not.

per month for the vaccinated group through the course of the study.
Table S2 presents the effect of maternal vaccination on birth weight

Additionally, 175 (6.4%) women experienced at least one episode of
influenza-like illness during pregnancy, whereas 2566 (93.6%) did not.

and pregnancy length, stratified by calendar time of vaccination (divided

Table S1 presents birthweight stratified by whether the mother

into 4-month blocks owing to the sample size). Compared with women in

experienced influenza or influenza-like illness. The adjusted regres-

the placebo group, birth weight was significantly higher among mothers

sion results showed that the neonates of mothers with laboratory-

vaccinated during January–April 2012 (mean difference 109 g, 95% CI

confirmed influenza at any point in pregnancy were on average 55 g

27–191), and during January–April 2013 (mean difference 112 g, 95%

(95% confidence interval [CI] −213 to 103) lighter at delivery than

CI 12–212). A statistically significant reduction was seen for those vacci-

neonates whose mothers did not have influenza, but the difference

nated during September–December 2011 (mean difference −101 g, 95%

was nonsignificant. Likewise, the neonates of mothers with influenza-

CI −185 to −17). Among women vaccinated during May–August 2011,

like illness at any point in pregnancy were significantly lighter at deliv-

statistically significant reductions in LBW (RR 0.70, 95% CI 0.55–0.89)

ery than were those of mothers who did not experience influenza-like

and SGA (RR 0.81, 95% CI 0.67–0.99) were seen. Statistically significant

illness (70 g, 95% CI −139 to −2). The total duration of illness was

reductions in preterm births were found among those vaccinated during

1–26 days (median 4 days) for those with influenza and 1–12 days

May–August 2012 (RR 0.55, 95% CI 0.33–0.92).
The vaccination effect on birth weight was stratified by exposure to

(median 3 days) for those with influenza-like illness. The duration of

high levels of influenza virus circulation in the third trimester (Table 4).

such illness was not associated with birth weight (data not shown).
The birth weight distribution in the placebo and vaccination

Although none of the birth weight effects remained statistically signifi-

groups is presented in Table 2 and Figure S4. Greater differences in

cant, the data were indicative of a dose-response pattern. Namely, the

birth weight between the placebo and vaccination groups were seen

greater the proportion of the third trimester exposed to high influenza

during periods of more intensive A/H1N1 or B/Yamagata circulation

circulation, the greater the magnitude of birth weight gain associated

(data not shown).

with vaccination (Table 4). This dose-response pattern could be observed

As previously reported,15 influenza vaccination increased mean
birth weight by 42 g (95% CI 8–76) but had no effect on pregnancy

when the analysis was limited to women who were vaccinated before
26 weeks, but the effects were not statistically significant (Table 4).

length (difference 0.07 weeks, 95% CI −0.09 to 0.24). A statistically sig-

When stratifying by timing of vaccination in pregnancy, an increase

nificant reduction was found for LBW (adjusted risk ratio 0.85, 95% CI

in birth weight was seen in each category, but was only statistically

0.75–0.97) but not for SGA or preterm birth.15 The breakdown of neo-

significant among women vaccinated before 26 weeks (48 g, 95% CI

nates by SGA, preterm, and LBW is shown in Table 3. Compared with

6–90) (Table 4).

the placebo group, the vaccinated group had a greater proportion of

A dose-response relationship between exposure to high influ-

infants in the term-AGA category (the lowest mortality risk) and lower

enza circulation and pregnancy length was observed but was not

TABLE 2

Birth weight distribution, by vaccine typea and vaccination status.
Vaccine 1

Birth weight

a

Placebo (n=993)

Vaccine (n=1030)

Placebo (n=368)

Combined
Vaccine (n=350)

Placebo (n=1361)

Vaccine (n=1380)

Mean, g

2749

2785

2796

2859

2762

2804

Median, g

2760

2800

2790

2860

2770

2810

Interquartile range, g

2460–3040

2520–3080

2520–3075

2560–3150

2470–3050

2520–3100

Range, g

820–4420

1260–4110

1360–4140

1590–4800

820–4420

1260–4800

Low birth weightb

278 (28.0)

239 (23.2)

87 (23.6)

76 (21.7)

365 (26.8)

315 (22.8)

Vaccine types are described in Appendix S1.
Values given as number (percentage).

b

Vaccine 2

|
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Vaccinated
Influenza circulaon levels

2800

1

2700

0.8

2600

0.6

2500

0.4

2400

0.2

2300

0

Influenza virus circulaon level (%)

1.2

May-11
Jun-11
Jul-11
Aug-11
Sep-11
Oct-11
Nov-11
Dec-11
Jan-12
Feb-12
Mar-12
Apr-12
May-12
Jun-12
Jul-12
Aug-12
Sep-12
Oct-12
Nov-12
Dec-12
Jan-13
Feb-13
Mar-13
Apr-13
May-13
Jun-13
Jul-13
Aug-13
Sep-13
Oct-13
Nov-13
Dec-13
Jan-14
Feb-14
Mar-14
Apr-14

Mean birthweight (g)

1.4

Placebo

2900

Timepoint

FIGURE 1
circulation.
Abbreviations: RRR, relative risk ratio; AGA, appropriate for gestational age; LBW, low birth weight; SGA, small for gestational age.
a
Preterm-SGA infants were all LBW.

Ref.

0.53 (0.27–1.05)

23 (1.8)

13 (1.0)

Ref.

0.73 (0.51–1.04)

76 (5.9)
Ref.

1.07 (0.77–1.47)

79 (6.1)
Ref.
241 (18.5)
Ref.

0.92 (0.75–1.14)

227 (17.5)

224 (17.1)

Ref.

Ref.

654 (50.3)
Placebo (n=1300)

Vaccinated (n=1307)

699 (53.5)

0.93 (0.61–1.41)
53 (16.0)
Ref.
Vaccinated (n=331)

Combined

193 (54.2)
Placebo (n=356)

Vaccine 2

187 (56.5)

Ref.
59 (16.6)
Ref.

222 (17.0)

0.86 (0.70–1.06)

90 (6.9)

59 (4.5)

0.83 (0.22–3.12)
4 (1.2)
0.67 (0.30–1.46)
0.98 (0.52–1.87)
56 (16.9)

Ref.

0.92 (0.72–1.17)
171 (17.5)
Ref.
Vaccinated (n=976)

512 (52.5)

Ref.
168 (17.8)
Vaccine 1

Placebo (n=944)

461 (48.8)

Ref.

61 (17.1)

0.95 (0.63–1.43)

20 (6.0)

11 (3.3)

Ref.
5 (1.4)
Ref.
Ref.
21 (5.9)

17 (4.8)

0.45 (0.20–1.01)
9 (0.9)
0.73 (0.49–1.09)
1.09 (0.75–1.57)
166 (17.0)

Ref.
180 (19.1)

0.83 (0.65–1.06)

70 (7.2)

48 (4.9)

Ref.
18 (1.9)
Ref.
Ref.
58 (6.1)

59 (6.3)

RRR
No. (%)
RRR
No. (%)
RRR
No. (%)
RRR
No. (%)
RRR
No. (%)
RRR

Term-SGA-not LBW
Term-AGA

No. (%)
Vaccination

TABLE 3

RRR of vaccination and categorical birth outcomes.

Term-SGA-LBW

Preterm-AGA-not LBW

Preterm-AGA-LBW

Preterm-SGAa

3000

69

Mean birth weight in relation to influenza virus

statistically significant (Table S3). However, a statistically significant
increase in pregnancy length was found among mothers who were
vaccinated between 26 weeks and less than 30 weeks, when at least
half of their third trimester had been exposed to high influenza virus
circulation. When removing the circulation stratification, there was
a statistically significant positive effect on pregnancy length among
those vaccinated between 26 weeks and less than 30 weeks, but not
for those vaccinated before or after that time (Table S3).
When the proportion of a pregnancy’s third trimester exposed to
high influenza virus circulation was examined as a continuous variable,
vaccination during periods of greater influenza virus circulation had a
greater positive effect on birth weight than vaccination during periods
of lower influenza virus circulation, but the effect modification was not
statistically significant. A positive trend of increased pregnancy length
was observed among vaccinated individuals with greater third trimester exposure to influenza circulation than with lower third trimester
exposure; however, the effect modification was not statistically significant (data not shown).

4 | DISCUSSION
Maternal influenza vaccination increased birth weight among live
births in the present study. The magnitude differed by season,
appearing greatest among pregnancies for which the third trimester occurred at a time of high influenza virus circulation; however,
the results were inconclusive. Sarlahi District in southern Nepal is
a subtropical region that experiences influenza virus circulation for
two-thirds of the year and is epidemiologically similar to other parts
of South Asia. Seasonal peaks of circulation appear to overlap temporally with an increased effect of vaccination on birth weight. In a
low-resource setting such as rural Nepal, vaccination delivery can be
logistically difficult; therefore, alternatives to year-round vaccination

70
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T A B L E 4 The effect of vaccination on birthweight (in g), stratified by extent of third-trimester exposure to high influenza circulation and
timing of vaccination in pregnancy.

Vaccination

Combined

Vaccinated at <26 wk

Vaccinated at 26–<30 wk

Vaccinated at ≥30 wk

n

n

n

n

β (95% CI)

β (95% CI)

β (95% CI)

β (95% CI)

0% to <25% of third trimester
in high circulation period
Placebo

1142

Ref.

779

Ref.

225

Ref.

138

Ref.

Vaccinated

1130

38 (−6 to 81)

766

42 (−11 to 95)

203

30 (−68 to 128)

161

39 (−85 to 163)

25% to <50% of third trimester
in high circulation period
Placebo

367

Ref.

244

Ref.

Vaccinated

384

21 (−49 to 90)

245

51 (−37 to 138)

94
114

Ref.

29

Ref.

−80 (−205 to 44)

25

109 (−136 to 353)

50% to <75% of third trimester
in high circulation period
Placebo

240

Ref.

136

Ref.

67

Ref.

37

Ref.

Vaccinated

236

66 (−32 to 165)

136

64 (−59 to 186)

64

32 (−157 to 222)

36

124 (−175 to 423)

75%–100% of third trimester
in high circulation period
Placebo

90

Ref.

43

Ref.

29

Ref.

18

Ref.

Vaccinated

86

111 (−51 to 273)

47

118 (−119 to 354)

24

304 (−14 to 622)

25

−86 (−397 to 225)

Combined
Placebo

1845

Ref.

1206

Ref.

416

Ref.

223

Ref.

Vaccinated

1843

42 (8 to 76)

1191

48 (6 to 90)

405

23 (−47 to 93)

247

48 (−52 to 148)

Abbreviation: CI, confidence interval.

should be considered. The present study also indicated a marginal

result from various maternal exposures, including nutrition, substance

reduction in the prevalence of infants born both preterm and SGA.

misuse, environment, and infection.21 Rates of malnutrition are high in

No clear trends were observed to link timing of vaccination during

Asia; therefore, it is possible that poor nutrition aggravates the adverse

pregnancy with the effects on birth weight.

effect of infectious disease. There is extensive evidence linking malnu-

Previous observational studies reported mixed results regarding

trition with increased susceptibility to, and/or severity of, infection.22 A

the effect of maternal influenza vaccination on birth outcomes. Data

study conducted in the Democratic Republic of Congo23 showed that

collected in the USA between 2004 and 2009 showed no effect on

the association between malaria and fetal growth restriction was only

preterm birth or SGA,19 although rates of these outcomes are much

present if women presented with poor nutritional indicators, such as

lower in the USA than in low-income countries. Data from the 2009

low body mass index and low mid-upper arm circumference. The pres-

US H1N1 influenza pandemic showed that preterm rates were 37%

ent study did not capture sufficient cases of influenza or influenza-like

lower (adjusted odds ratio 0.63, 95% CI 0.47–0.84) for the vaccinated

illness to stratify the analyses by maternal nutrition status.

versus the non-vaccinated, but there was a minimal birth weight effect

The present study examined only the effect of vaccination on birth

and no change in SGA or LBW.20 Although these observational studies

weight and pregnancy length; however, there is evidence to suggest that

adjusted for confounders, residual confounding is likely because vacci-

influenza vaccination might positively impact fetal and neonatal health

nated women likely differ in characteristics from unvaccinated women.

outcomes through other mechanisms. Animal studies have indicated

Four maternal influenza vaccination trials have been conducted to

effects of maternal influenza infection on fetal brain development,24

date, including the Nepal Mothers’ Gift Trial.15,16 A Bangladeshi study

and an analysis of the 1918 influenza pandemic found excess risk of

found only a statistically significant increase in birth weight and a

cardiovascular disease among individuals born during this pandemic.25

decrease in SGA rate during the high influenza virus circulation period.14

The present study found a substantial reduction in preterm-SGA inci-

Studies conducted in South Africa13 and Mali12 found no effect on birth

dence among vaccinated mothers. Preterm-SGA infants experience the

weight or LBW, irrespective of influenza virus circulation. The consis-

highest risk of neonatal and postneonatal mortality. Asian data that

tency of the present findings with the Bangladeshi study14 could imply

were comprised predominantly of South Asian studies showed a 17-

a regional difference. The LBW and SGA rates are substantially higher

fold increase in neonatal mortality risk when comparing preterm-SGA

in Asia than in Sub-Saharan Africa,21 which might indicate varying eti-

with term-AGA infants.8 Rates of stillbirth have also been reported to

ological factors that affect birth weight. An outcome of LBW, which

be higher among growth-restricted and/or preterm fetuses.26 Although

is comprised of preterm delivery and/or fetal growth restriction, can

the present sample size was not large enough to detect differences
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in neonatal mortality, a protective effect against mortality might be
expected with the reduction in the proportion of preterm-SGA infants.
The present study could not determine what period in pregnancy

2.

would be associated with the largest effect from exposure to influenza
virus. Given that the greatest fetal weight gain occurs late in pregnancy,

27

the present study focused on such exposure during the third

trimester; however, exposure at an earlier stage in pregnancy could

3.
4.

trigger inflammatory responses that affect other health outcomes.
In attempting to understand the interaction between seasonality of
influenza virus circulation and the stages of pregnancy, the present
study could not definitively identify an ideal time for maternal influenza vaccination. Additionally, the viral surveillance performed might
have been limited because nasal swabs for influenza testing were
taken only among women who reported a febrile respiratory illness.
In conclusion, maternal influenza vaccination exerted the greatest

5.
6.
7.

8.

effect on birth weight among pregnant women who were exposed to
high influenza virus circulation during the third trimester. A strategy

9.

of seasonal maternal influenza vaccination in resource-limited settings
could potentially increase birth weight during periods of high influenza
circulation. Taking into consideration the barriers to providing year-

10.

round vaccination, it may be possible to target key times of the year to
maximize the impact on birth outcomes.
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